Business Wire

London, New York and Tokyo Remain the World's Most Attractive Cities

Jaa

London, New York, and Tokyo were again named as the most comprehensively attractive cities in the Global Power City Index (GPCI) 2017 report published today by The Mori Memorial Foundation’s Institute for Urban Strategies, a research institute established by Mori Building, a leading urban developer in Tokyo. First released in 2008, the annual GPCI report evaluates and ranks 44 major cities according to their “magnetism,” or their overall power to attract creative individuals and enterprises from around the world. Cities are rated on the basis of 70 detailed indicators in six categories: “Economy”, “R&D”, “Cultural Interaction”, “Livability”, “Environment”, and “Accessibility”.

This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171011005011/en/

Overall ranking of all 44 cities and function-specific ranking of top 10 cities (Graphic: Business W ...

Overall ranking of all 44 cities and function-specific ranking of top 10 cities (Graphic: Business Wire)

This year, the top three cities - London, New York and Tokyo – all retained their slots, with London maintaining its No. 1 position for the sixth year running. Tokyo, which claimed the No. 3 position for the first time last year, further improved its scores in the field of “Cultural Interaction”, closing the gap on second-placed New York. Paris experienced a significant decline in its ranking in the “Livability” category, due largely to the recent terrorist attacks, but the host city of the 2024 Olympic and Paralympic Games is expected to rise above the competition in the coming years by further strengthening its “Accessibility” scores and recovering its “Cultural Interaction” ratings.

Overall, European cities scored highly on “Livability” and “Environment”, maintaining their reputations as the world’s most livable cities, while U.S. cities maintained their high scores in the areas of “R&D”, underscoring the attraction of these cities for researchers and innovators. Seven Asian cities, topped by Beijing, Tokyo, Shanghai and Hong Kong, featured in the top 10 in the “Economy” category, followed by Dubai, which featured for the first time in this year’s report and achieved strong ratings for its corporate tax rates, ranking No.11 in that indicator category.

Commented Hiroo Ichikawa, Executive Director of The Mori Memorial Foundation, “In the last 10 years, the report has shown that the power of cities has been changing as a result of changes in the macro environment. Our report suggests that a city’s overall power cannot be determined by a single factor, such as economy, but needs to take into account the many factors that define the city. Rapid urbanization and globalization pose both challenges and opportunities for cities, so for cities to thrive, they need to accurately assess their specific strengths and weaknesses, as well as their relative positioning against other cities. We believe that our GPCI report can help policy makers and global companies achieve smarter planning and decision-making in their efforts to thrive in today’s highly competitive global environment.”

Key Highlights

  • London’s core strengths lay in the category of “Cultural Interaction”, which helped the city keep its No.1 position overall for the tenth consecutive year. London continued to maximize its overall strengths by improved scores in the indicators of GDP Growth Rate and Level of Political, Economic and Business Risk. While there remains some uncertainty surrounding the U.K.’s exit from the EU, London’s balanced strengths across several categories mean the city has the potential to turn challenges into opportunities, extending its commanding lead and continuing forward as the top-ranked city in which to live and work.
  • New York, in second place overall, increased its scores in the “Economy” category due to improvements in its Nominal GDP and GDP Growth Rate, but failed to make any significant headway in its overall score, owing to weaker showings this year in the category of “Cultural Interaction”.
  • Tokyo maintained its No.3 position and further closed the gap on New York, largely due to improved “Cultural Interaction” indicators, in particular the Number of Visitors from Abroad. Tokyo also further improved its scores in the field of “Accessibility”, due largely to an increase in the number of direct flight connections between Tokyo and overseas cities.
  • Dubai and Buenos Aires made their first-ever appearances in the GPCI in 2017 with respective overall rankings of 23rd and 40th. Dubai posted strengths in “Cultural Interaction” (9th) and the “Economy” (11th), thanks mainly to strong evaluations in the area of Number of Luxury Hotel Guest Rooms and Corporate Tax Rates.
  • In other parts of the world, Sydney climbed four spots this year to edge its way into the top 10 for the first time in seven years. Cities such as Los Angeles (in 11th position overall), Beijing (13th), San Francisco (17th), Amsterdam (7th), Berlin (8th) and Frankfurt (12th) all significantly improved their rankings from last year, as did Vienna (14th), Stockholm (16th), Zurich (18th) and Copenhagen (20th).

For more details, see:
http://www.mori-m-foundation.or.jp/english/ius2/gpci2/index.shtml
www.mori-m-foundation.or.jp/english/aboutus2/index.shtml#about_strategies

Contact information

Media Inquiries
Weber Shandwick
Rutsuko Nakajima, +81 (0)90 9006 5841
Masashi Nonaka, +81 (0)80 1037 7879
moribldg@webershandwick.com

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

Dole’s Joint Venture Recycling Company Celebrates 25 Years21.5.2018 14:00Tiedote

Dole Food Company announced today that Recyplast S.A., an innovative plastic recycling company based in Costa Rica and with joint ownership including a subsidiary of Dole Fresh Fruit, recently surpassed 25 years in its mission to dramatically reduce and reuse agricultural waste. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180521005160/en/ Raul Martinez (right), General Manager of Dole Standard Fruit de Costa Rica, receives a plaque from Jose Miguel Ramirez, General Manager of Recyplast, in recognition of the contribution of Dole's banana plantations in the correct handling, storage, and provision of field plastic waste. The plastic recycling facility pioneered the collection of field plastics after use in banana growing operations in Costa Rica. This reuse and recycling process includes reclamation of plastic bags that protect bananas from weather and insects, as well as the collection of plastic twine used to prop the ba

ViiV Healthcare Receives EU Marketing Authorisation for Juluca (dolutegravir/rilpivirine), the First 2-Drug Regimen, Once-Daily, Single-Pill for the Treatment of HIV21.5.2018 13:11Tiedote

ViiV Healthcare, the global specialist HIV company, majority owned by GlaxoSmithKline, with Pfizer Inc. and Shionogi Limited as shareholders, today announced that the European Commission has granted marketing authorisation for Juluca (dolutegravir 50mg/rilpivirine 25mg) for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults who are virologically suppressed (HIV-1 RNA <50 copies/mL) on a stable antiretroviral regimen for at least six months with no history of virological failure and no known or suspected resistance to any non-nucleoside reverse transcriptase inhibitor or integrase inhibitor.1 Juluca is a 2-drug regimen of dolutegravir (ViiV Healthcare), the most widely prescribed integrase inhibitor worldwide,2 and rilpivirine (Janssen Sciences Ireland UC, part of the Janssen Pharmaceutical Companies of Johnson & Johnson).1 Deborah Waterhouse, CEO ViiV Healthcare said, “The European Commission Decision for Juluca is very positive news for people living with

Janssen Announces European Commission Approval of JULUCA®▼ (dolutegravir/rilpivirine), the First Two-Drug Regimen, Once-Daily, Single-Pill for the Treatment of HIV-121.5.2018 13:06Tiedote

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the European Commission has granted marketing authorisation for JULUCA® (dolutegravir 50mg [ViiV Healthcare]/rilpivirine 25mg [Janssen Sciences Ireland UC]).1 ViiV Healthcare, as the marketing authorisation holder, will market dolutegravir/rilpivirine in all countries in the European Union and European Economic Area. Dolutegravir/rilpivirine is the first two-drug regimen, once-daily, single-pill for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults who are virologically suppressed (HIV-1 RNA <50 c/mL) on a stable antiretroviral regimen for at least six months with no history of virological failure and no known or suspected resistance to any non-nucleoside reverse transcriptase inhibitor (NNRTI) or integrase inhibitor (INI).1 “The European Commission Decision for dolutegravir/rilpivirine marks a significant milestone in our 25-year commitment to make HIV history,” said Brian Woo

Chugai Presents Results of Two Pivotal Phase lll Studies for its Bispecific Antibody HEMLIBRA® at WFH 201821.5.2018 12:44Tiedote

Chugai Pharmaceutical Co., Ltd. (TOKYO:4519) today announced that full results from HAVEN 3 study (NCT02847637) and HAVEN 4 study (NCT03020160) evaluating Chugai’s hemophilia A treatment HEMLIBRA® [generic name: emicizumab (genetical recombination)] are being presented at the World Federation of Hemophilia 2018 World Congress held in Glasgow, Scotland from May 20 to 24. HAVEN 3 study is conducted in people with hemophilia A without inhibitors, and HAVEN 4 study is conducted in people with hemophilia A with or without inhibitors. Results from both studies will be presented as late-breaking abstracts. “The results from HAVEN 3 study demonstrate that HEMLIBRA, which was created with Chugai’s proprietary antibody engineering technologies, can reduce the bleeding risk in people with hemophilia A without inhibitors. The intra-patient comparison in this study also shows a statistically significant reduction in bleeding by HEMLIBRA prophylaxis compared to factor VIII therapy, the current stand

STATS Unveils STATS GPS, the Most Advanced Technology for Athlete Monitoring21.5.2018 10:00Tiedote

Today, STATS, the worldwide leader in sports data and intelligence, unveiled STATS GPS, an innovative system that uses a revolutionary 50-Hz sampling frequency to provide the most advanced real-time GPS technology available. STATS GPS allows teams to monitor player performance with customizable metrics like accelerations/decelerations, energy expenditure, count of zone entries, and time, distance and power thresholds. The innovative solution uses real 50-Hz sampling frequency and allows practitioners to monitor up to 100 players in real-time and post session with over 300 GPS, IMU and HR derived metrics. Embedded in the GPS vests are textile heart-rate sensors, making STATS GPS the most advanced technology on the market. “Teams and conditioning coaches need the latest technology to ensure players stay at peak health and fitness during long seasons,” said Ryan Paterson, Chief Global Officer at STATS. “With STATS GPS’ new 50-Hz technology, teams can instantly get performance information,

Sofinnova Partners Appoints Dr. Martin T. Rothman as Venture Partner21.5.2018 09:00Tiedote

Sofinnova Partners, a leading European venture capital firm specialized in Life Sciences, has appointed Dr. Martin T. Rothman as Venture Partner. Dr. Rothman brings forty years of experience and a strong international network in the medical field to Sofinnova Partners. As Venture Partner, Dr. Rothman will focus on helping the team identify and evaluate promising medical device companies and on mentoring entrepreneurs and physicians launching clinical innovations. Sofinnova Partners and Dr. Rothman have closely collaborated over many years. Dr. Rothman is the founder of LimFlow and an independent board member of HighLife, both portfolio companies of Sofinnova Partners. Until recently, he was Vice President of medical affairs for coronary, structural heart and renal denervation for Medtronic, based in Santa Rosa (CA), a position he held since 2010. He was involved in the development of the renal denervation program, the Trans-Aortic Valve Replacement program, and the Medtronic percutaneo

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme